Pharmaceutical Executive
"Tired of your old birth-control routine?" the spot asks. "Maybe it's time to break free from the pack with NuvaRing."
BREAK FREE FROM THE PACK
TBWA/WorldHealth
BRAND NuvaRing CLIENT Schering-Plough CLOCKWISE FROM FRONT LEFT: Leticia Freytes, account executive; Matthew Damron, group account director; Leo Zanis, associate creative director; Gary Scheiner, executive creative director; Cristin Ryan, account director; Anne Devereux, chairman and CEO
"Tired of your old birth-control routine?" the spot asks. "Maybe it's time to break free from the pack with NuvaRing."
Schering-Plough's DTC ad "Break Free from the Pack" presented a platform built on disruption—not one of pharma's favorite themes. "Disruption is a scary word, but it doesn't necessarily have to be scary or mean crazy," says Gary Scheiner, executive creative director and main writer, TBWA/WorldHealth. "Disruption is merely a way of dismantling the status quo and replacing it with something bold and new."
Working together, client and agency decided on a big, disruptive idea. They were inspired by the work of 1930s film director Busby Berkeley, who is best known for elaborate synchronized dance routines on stage and in water.
TBWA/WorldHealth worked with world-renowned fashion photographer Matthew Rolston to add beautiful staging and tell the NuvaRing story. Identically clad swimmers communicated the monotonous routine of taking oral contraceptives by chanting the original song "Monday, Tuesday, Wednesday..." When the heroine realizes she can break from the routine, she steps out of the pool, tears the day off her chest, and becomes the modern woman who chooses NuvaRing.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.